Compare Synopsys, Inc. (SNPS) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Synopsys, Inc. vs Viatris Inc — how do they compare? Synopsys, Inc. trades at $388.45 (market cap $72.47B), while Viatris Inc trades at $17.54 (market cap $19.79B). The key difference: Synopsys, Inc. is far larger — about 3.7× Viatris Inc's market cap, and Viatris Inc pays a 2.83% dividend while Synopsys, Inc. pays none. Which is the better fit depends on your goals.
| SNPS | VTRS | |
|---|---|---|
Market Cap | $72.47B | $19.79B |
Sector | Technology | Health |
52-Week High | $645.59 | $17.39 |
52-Week Low | $378.46 | $8.74 |
Enterprise Value | $80.82B | $32.00B |
Dividend Yield | — | 2.83% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Synopsys (SNPS) trades at $388.84, up 1.19% on the day, with a bearish technical signal despite recent earnings beats. The stock faces headwinds from semiconductor sector volatility but maintains strong analyst support with an 82.76% buy rating. Recent news highlights the company's strategic pivot toward AI design tools and margin expansion following its Ansys integration, positioning it as a key enabler in the chip design ecosystem despite near-term price pressure.
Outlook remains positive long-term due to SNPS's dominant EDA market position and AI-driven growth opportunities, though investors face risks from cyclical semiconductor demand and integration execution. The consensus price target of $559.50 implies significant upside if the company delivers on its AI strategy and margin improvements.
Viatris (VTRS) trades at $17.59, up 1.74% today, with a bullish technical signal and consistent earnings beats in recent quarters. The company reported revenue of $14.3B for 2025 but posted a net loss of $3.51B, reflecting margin pressures. Positive pipeline developments include FDA acceptance of a new drug application for fast-acting meloxicam, with a PDUFA date set for December 2026. Cash flow from operations remains strong at $2.32B, supporting debt reduction efforts.
The outlook is mixed: analyst consensus targets $20.00 (13.7% upside), but profitability challenges and high debt levels pose risks. Investment appeal hinges on successful pipeline execution and margin recovery, while competitive and regulatory pressures in the generics market remain key watchpoints for shareholders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Synopsys, Inc.
Synopsys is a provider of electronic design automation software, intellectual property, and software integrity products. EDA software automates the chip design process, enhancing design accuracy, productivity, and complexity in a full-flow end-to-end solution. The firm's growing SI business allows customers to continuously manage and test the code base for security and quality. Synopsys' comprehensive portfolio is benefiting from a mutual convergence of semiconductor companies moving up-stack toward systems-like companies, and systems companies moving down-stack toward in-house chip design. The resulting expansion in EDA customers alongside secular digitalization of various end markets benefits EDA vendors like Synopsys.
Read more on SNPS →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
